ABBV


AbbVie’s SKYRIZI Obtains FDA Approval to Treat Active Psoriatic Arthritis

This article was originally published on TipRanks.com AbbVie (NYSE: ABBV) has received U.

AbbVie’s RINVOQ Receives FDA Approval; Street Says Buy

This article was originally published on TipRanks.com AbbVie, Inc.

AbbVie Gets Breakthrough Therapy Designation for Lung Cancer Treatment

This article was originally published on TipRanks.com.

AbbVie Updates RINVOQ Indications for the Treatment of RA in the U.S.

This article was originally published on TipRanks.com Biopharmaceutical company AbbVie (ABBV) updated the U.

AbbVie’s Gets EC Approval for SKYRIZI

AbbVie (ABBV) has received the European Commission’s (EC) approval for interleukin-23 (IL-23) inhibitor SKYRIZI (risankizumab) to be used separately or with methotrexate (MTX) …

AbbVie Presents Data from Two Phase 3 Trials on Risankizumab

AbbVie (ABBV) has presented integrated data from two Phase 3 clinical trials, KEEPsAKE 1 and KEEPsAKE 2. These studies are designed to evaluate the efficacy and safety of risankizumab (SKYRIZI) in adult …

AbbVie’s 2021 Earnings Outlook Exceeds Estimates; Shares Up 4.6%

Biopharmaceutical company AbbVie (ABBV) provided upbeat guidance for 2021 after it posted better-than-expected earnings for the third quarter of 2021 on Friday. The …

AbbVie’s ABBV-951 Phase 3 Study Reflects Optimism; Shares Rise

Shares of AbbVie (ABBV) rose 1.2% to close at $109.

AbbVie Unit To Acquire Soliton For $550M To Boost Aesthetics Unit

AbbVie’s (ABBV) Allergan Aesthetics is to acquire Soliton (SOLY) plus its Rapid Acoustic Pulse device, which was recently approved by the U.S.

AbbVie Raises EPS Guidance After 1Q Earnings Beat

AbbVie (ABBV) is off to a good start going by its impressive 1Q 2021 results. Net revenues increased by 51% year-over-year to $13.

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts